Advisory · August 2026

Scalp Psoriasis, Plainly

A common, treatable, misread condition — what it is, how to tell it from dandruff, and what the evidence supports.

Owls & Wolves · Editorial

Psoriasis on the scalp is common, treatable, and misread — first by the person who has it, sometimes by the first practitioner they see. It is mistaken for dandruff, for a reaction to a new shampoo. It responds to none of the things those other conditions respond to, and the gap between what is tried and what would actually help can run for years.1

Scalp psoriasis, plainly
Edges, more than scale, are the tell.

What scalp psoriasis is.

Psoriasis is a chronic, immune-mediated condition in which skin cells proliferate far faster than the skin can shed them. On the scalp, this presents as well-defined plaques: thicker than a flake, more silver than a yellow scale, sitting on skin that is often pink or red beneath. The plaques tend to have edges you can trace. They tend to recur in the same places — the hairline, behind the ears, the back of the neck, the crown.2

About half of people with plaque psoriasis on the body have scalp involvement at some point. For a meaningful minority, the scalp is where it appears first or where it remains worst.3 It is not contagious, not caused by hygiene, not caused by stress alone — though stress, infection, and certain medications can trigger flares in someone already predisposed.4

How to tell it from dandruff.

This is the question most people get wrong, and the one that changes what to do next. Seborrheic dermatitis — common dandruff — produces a yellowish, greasy scale on pink skin, often diffuse across the scalp, often involving the eyebrows, the sides of the nose, the chest. The scale is loose. It comes off in water. It responds to antifungal shampoos within a few weeks.5

Scalp psoriasis produces a silvery-white scale, often thicker, often layered, sitting on skin that is more sharply demarcated. The plaques have edges. They extend just past the hairline onto the forehead or behind the ear in a way dandruff usually does not.6 Edges, more than scale color or scale lift, are the single most useful tell at home; antifungal shampoos do not resolve scalp psoriasis, though they sometimes help marginally because the two conditions can coexist.5,6

If both are present at once, the term sebo-psoriasis gets used, and it is more than a label — the treatment is layered, not binary.7

What triggers it, and what doesn’t.

The honest answer is that psoriasis has a strong genetic component and a smaller, more variable set of environmental triggers. Streptococcal infections can precipitate a flare, particularly in younger patients. Certain medications — lithium, beta-blockers, antimalarials, abrupt withdrawal of oral steroids — are well documented to worsen psoriasis.8 Stress is real but less reliably causal than it is often credited for; managing it is worth doing for its own reasons.

What does not cause psoriasis: shampoo, conditioner, hair color done by a competent professional, the wrong diet (with rare exceptions), or moral failing of any kind. The instinct to find the one thing that “started it” is understandable. It is also usually a distraction from the thing that would actually help.

What the evidence supports.

Treatment for scalp psoriasis follows a clear tier system, well-established in international guidelines.9

The first tier is topical: a medium-to-high potency corticosteroid, often paired with a vitamin D analog (calcipotriene). Used in short courses or rotated, this combination has decades of randomized data behind it and resolves or substantially improves most cases.10 Formulation matters more on the scalp than elsewhere — a foam or solution penetrates hair better than a thick cream — and adherence improves dramatically when the vehicle is one the patient will actually use.

The second tier is phototherapy. Narrow-band UVB is effective but logistically difficult on the scalp because hair blocks light; targeted excimer laser is sometimes used for plaques resistant to topicals.11

The third tier is systemic therapy — methotrexate, cyclosporine, oral retinoids — and the fourth is biologic therapy, the monoclonal antibodies that target the immune pathways driving psoriasis. The biologics are reserved for moderate-to-severe disease, particularly when psoriasis affects more than the scalp. They are remarkably effective and now well-studied for long-term use.12

The point of laying out the tiers is not to suggest everyone should ascend them, but to make the path visible. Most scalp psoriasis is well controlled at the first tier, given the right formulation and a willingness to use it consistently.

What to leave alone.

Picking. The single most common way scalp psoriasis becomes worse is the same way every chronic skin condition becomes worse — repeated mechanical trauma to plaques that are already inflamed. The Koebner phenomenon, well described in psoriasis, is the tendency for new lesions to appear in areas of skin injury.13 A scalp that is picked at, scratched hard, or scrubbed with a brush is a scalp where psoriasis spreads.

Over-the-counter products marketed as “psoriasis shampoos” are a mixed category. Coal tar and salicylic acid both have real, modest evidence behind them — tar as an anti-proliferative, salicylic acid as a keratolytic that lifts scale.14 They are reasonable adjuncts. They are not sufficient as monotherapy for active disease.

The honest summary.

Scalp psoriasis is common, recognizable when you know what to look for, and treatable in tiers that begin with simple topicals and have somewhere to go if those are not enough. The most expensive mistake is not which product to start with — it is the years lost calling it dandruff. If the scale is silvery, the edges are sharp, and antifungal shampoos have not worked, the conversation to have is with a dermatologist, not a drugstore aisle.

Sources

  1. Papp K, et al. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol. 2007;21(9):1151–60.
  2. Blakely K, Gooderham M. Management of scalp psoriasis: current perspectives. Psoriasis (Auckl). 2016;6:33–40.
  3. Chan CS, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6):962–71.
  4. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94.
  5. Borda LJ, Wikramanayake TC. Seborrheic dermatitis and dandruff: a comprehensive review. J Clin Investig Dermatol. 2015;3(2):10.13188/2373–1044.1000019.
  6. van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol. 2001;2(3):159–65.
  7. van de Kerkhof PC, et al. Psoriasis of the face and flexures. J Dermatolog Treat. 2007;18(6):351–60.
  8. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol. 2000;1(3):159–65.
  9. Elmets CA, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy. J Am Acad Dermatol. 2021;84(2):432–470.
  10. Mason AR, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013;(3):CD005028.
  11. Mehraban S, Feily A. 308nm excimer laser in dermatology. J Lasers Med Sci. 2014;5(1):8–12.
  12. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960.
  13. Sagi L, Trau H. The Koebner phenomenon. Clin Dermatol. 2011;29(2):231–6.
  14. Jacobi A, Mayer A, Augustin M. Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review. Dermatol Ther (Heidelb). 2015;5(1):1–18.
← Back to Advisory